Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men
- PMID: 23324657
- PMCID: PMC3740057
- DOI: 10.1097/QAD.0b013e32835eca9b
Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men
Abstract
Objective: Among HIV-infected patients, high rates of myocardial infarction (MI) and sudden cardiac death have been observed. Exploring potential underlying mechanisms, we used multidetector spiral coronary computed tomography angiography (coronary CTA) to compare atherosclerotic plaque morphology in HIV-infected patients and non-HIV-infected controls.
Methods: Coronary atherosclerotic plaques visualized by CTA in HIV-infected (101) and non-HIV-infected (41) men without clinically apparent heart disease matched on cardiovascular risk factors were analyzed for three vulnerability features: low attenuation, positive remodeling, and spotty calcification.
Results: Ninety-five percent of HIV-infected patients were receiving ART (median duration 7.9 years) and had well controlled disease (median CD4 cell count, 473 cells/μl; median HIV RNA <50 copies/ml). Age and traditional cardiovascular risk factors were similar in HIV-infected patients and controls. Among the HIV-infected (versus control) group, there was a higher prevalence of patients with at least one: low attenuation plaque (22.8 versus 7.3%, P = 0.02), positively remodeled plaque (49.5 versus 31.7%, P = 0.05) and high-risk 3-feature plaque (7.9 versus 0%, P = 0.02). Moreover, patients in the HIV-infected (versus control) group demonstrated a higher number of low attenuation plaques (P = 0.01) and positively remodeled plaques (P = 0.03) per patient.
Conclusion: Our data demonstrate an increased prevalence of vulnerable plaque features among relatively young HIV-infected patients. Differences in coronary atherosclerotic plaque morphology - namely, increased vulnerable plaque among HIV-infected patients - are here for the first time reported and may contribute to increased rates of MI and sudden cardiac death in this population.
Figures


References
-
- Lewden C, Chene G, Morlat P, Raffi F, Dupon M, Dellamonica P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr. 2007;46:72–77. - PubMed
-
- Palella FJ, Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27–34. - PubMed
-
- Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med. 2006;145:397–406. - PubMed
-
- Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, Law M, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS. 2010;24:1537–1548. - PubMed
Publication types
MeSH terms
Grants and funding
- P30 DK040561/DK/NIDDK NIH HHS/United States
- R01 HL095123/HL/NHLBI NIH HHS/United States
- R01 HL112661/HL/NHLBI NIH HHS/United States
- M01 RR001066/RR/NCRR NIH HHS/United States
- KL2 TR000168/TR/NCATS NIH HHS/United States
- R01HL095123/HL/NHLBI NIH HHS/United States
- K24 DK064545/DK/NIDDK NIH HHS/United States
- UL1 RR025758/RR/NCRR NIH HHS/United States
- M01-RR-01066/RR/NCRR NIH HHS/United States
- 1 UL1 RR025758-01/RR/NCRR NIH HHS/United States
- 8KL2TR000168-05/TR/NCATS NIH HHS/United States
- P30DK040561/DK/NIDDK NIH HHS/United States
- K23 HL092792/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials